Compare TNON & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TNON | NEUP |
|---|---|---|
| Founded | 2012 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.8M | 10.3M |
| IPO Year | 2022 | N/A |
| Metric | TNON | NEUP |
|---|---|---|
| Price | $1.06 | $3.80 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $3.00 | ★ $21.00 |
| AVG Volume (30 Days) | 73.3K | ★ 83.6K |
| Earning Date | 11-13-2025 | 02-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $3,233,000.00 | ★ $15,649,448.00 |
| Revenue This Year | $19.56 | N/A |
| Revenue Next Year | $71.06 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.85 | $2.90 |
| 52 Week High | $5.85 | $21.40 |
| Indicator | TNON | NEUP |
|---|---|---|
| Relative Strength Index (RSI) | 42.23 | 35.97 |
| Support Level | $1.06 | $3.70 |
| Resistance Level | $1.13 | $4.15 |
| Average True Range (ATR) | 0.04 | 0.24 |
| MACD | -0.00 | 0.10 |
| Stochastic Oscillator | 12.00 | 9.47 |
Tenon Medical Inc is a medical device company that has developed a novel, minimally invasive approach to the sacroiliac joint (the SI Joint) using a single, robust, titanium implant for the treatment of the common types of SI Joint disorders that cause lower back pain. The Company is focused on three commercial opportunities; Primary SI Joint procedures, Revision procedures of failed SI Joint implants, and SI Joint fusion adjunct to a spine fusion construct. The company derives the majority of its revenue from sales of The Catamaran System to a limited number of clinicians.
Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.